Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00127478 · ClinicalTrials.gov registry record · Phase 2
A Long Term Safety Study With Atrasentan
A Phase 2 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 2
- Development phase
- 166
- Enrollment target
NCT00127478 is a Phase 2 study that has completed, run by Abbott. The registered enrollment target is 166 participants.
The verdict
NCT00127478, a Phase 2 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 166 participants
- Enrollment target
Study Summary
The primary purpose of the study is to evaluate long-term safety and tolerability of atrasentan 10 mg in men with hormone refractory prostate cancer.
Interventions
- DRUG Atrasentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2001-07 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00127478
The ClinicalTrials.gov registry entry for NCT00127478 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atrasentan is the first listed.
NCT00127478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00127478 about?
NCT00127478 is a clinical study titled "A Long Term Safety Study With Atrasentan". The primary purpose of the study is to evaluate long-term safety and tolerability of atrasentan 10 mg in men with hormone refractory prostate cancer.
What is the current status of trial NCT00127478?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 166 participants. The study started on 2001-07. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00127478?
The interventions under investigation include: Atrasentan (DRUG).
Who is sponsoring clinical trial NCT00127478?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.